IS THERE A MORTALITY BENEFIT WITH RENIN-ANGIOTENSIN SYSTEM (RAS) INHIBITION IN AFRICAN AMERICANS (AA) WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF)?

IS THERE A MORTALITY BENEFIT WITH RENIN-ANGIOTENSIN SYSTEM (RAS) INHIBITION IN AFRICAN AMERICANS (AA) WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF)?

Survival analysis performed using Kaplan-Meier and multivariate Cox regression models adjusting for age, gender, NYHA class, EF, DM, HTN, hypercholesterolemia, smoking, angina, beta blockers, ACEIs, ARBs, statins, aldactone and bidil therapy Results In 594 AAs with HF 303 (51%) in SHF and 226 (38%)...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the American College of Cardiology 2012-03, Vol.59 (13), p.E960-E960
Hauptverfasser: Valadri, Ravinder R., Veledar, Emir, gadesam, radhika, Cardona, Saumeth, Cross, Jo Ann, Strayhorn, Gregory, Bloom, Heather, Oduwole, Adefisayo, Lurgio, David De, Butler, Javed, Ofili, Elizabeth, Onwuanyi, Anekwe
Format: Artikel
Sprache:eng
Schlagworte:
Cardiology
Drug therapy
Fractions
Mortality
Survival analysis
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Survival analysis performed using Kaplan-Meier and multivariate Cox regression models adjusting for age, gender, NYHA class, EF, DM, HTN, hypercholesterolemia, smoking, angina, beta blockers, ACEIs, ARBs, statins, aldactone and bidil therapy Results In 594 AAs with HF 303 (51%) in SHF and 226 (38%) in HFPEF were on therapy with RASIs.
ISSN:0735-1097
1558-3597
DOI:10.1016/S0735-1097(12)60961-9